Aegis Sciences Corporation

The White House ONDCP recently issued a drug threat notice for cychlorphine (N-Propionitrile chlorphine), a novel synthetic opioid linked to at least 55 deaths nationally. (https://lnkd.in/gHumuzXV). It was first identified by the The Center for Forensic Science Research & Education, and is estimated to be approximately 10x more potent than fentanyl. (https://lnkd.in/gBDnXv-v) It is often co-detected with other drugs including novel psychoactive substances (NPS), which may increase overdose risk. Aegis is committed to keeping pace with emerging drug threats and providing clinicians with relevant testing for designer opioids and other NPS. Since mid-2025, Aegis has detected N-propionitrile chlorphine in 14 states. Learn more here: https://lnkd.in/e2nTq5zP #AegisLabs #NPSInsights #Cychlorphine #OverdoseRisk #PublicHealth #EmergingDrugTrends 

Pharmacy fill records offer only indirect evidence of medication adherence and cannot confirm whether a patient ingested a medication. They may also be misleading due to early refills, medication stockpiling, use of multiple pharmacies, or fragmented care across systems. In behavioral health populations, these limitations are even more significant because fill records fail to detect non-prescribed medication use, diversion, or self-medication. Definitive medication adherence testing provides objective, clinically actionable insight that helps clinicians make more informed treatment decisions and improve patient care. Learn more about Aegis adherence testing today: https://lnkd.in/ef6dR7mV #AegisLabs #MedicationMonitoring #Adherence #DefinitiveTesting #BehavioralHealth

Tomorrow, Aegis Sciences Corporation's Sr. Director, Clinical Affairs, Dr. Joshua Schrecker, will be speaking on the Overdose Response Strategy's (https://orsprogram.org/) Trends, Analysis & Threats (TAT) webinar at 1pm (CT)/2pm (EST). Dr. Schrecker will present an overview of emerging trends among individuals using illicit substances including those entering treatment and other clinical settings. Register for the event here: https://lnkd.in/eZCp4YpC #AegisLabs #EmergingDrugTrends #IllicitSubstances

ICYMI: During last week's clinical webinar, our very own, Dr. Chris Burke, Clinical Pharmacist, discussed the clinical and practical implications of Point-of-Care Testing (POCT) vs Definitive Testing. View on-demand here: https://lnkd.in/eidbjtxk #AegisLabs #Benzodiazepines #POCT #DefinitiveTesting #OverdoseRisk #Opioids #AddictionMedicine #PublicSafety

Point-of-Care (POCT) benzodiazepine testing plays an important role, but it should not be the final answer in every case. Immunoassays were designed around older drug structures and have limited sensitivity for many commonly prescribed and emerging benzodiazepines. Definitive LC-MS/MS testing provides broader coverage, lower detection limits, and clearer answers when results will affect care. Strategic test selection, guided by clinical risk rather than reflex algorithms alone, helps avoid missed exposures and supports better clinical decisions in behavioral health, pain management, and addiction medicine.    Learn more about the implications of POCT vs Definitive testing during our upcoming clinical webinar. Register today: https://lnkd.in/gBJhT3W3 #AegisLabs #Benzodiazepines #POCT #DefinitiveTesting #OverdoseRisk #Opioids #AddictionMedicine #PublicSafety

As NatCon26 continues, make sure to stop by our booth #1031 to learn more about Aegis. Today, Dr. Hope Randle, PharmD, BCPS, BCPP will be presenting on the topic, “Medication Adherence and High-Risk Substance Use: Insights from a Behavioral Health Population” on from 12:30pm-1pm/MDT.     Link to poster: https://lnkd.in/e3F-hNGB #NatCon26 #AegisLabs #MentalHealth #BehavioiralHealth #Wellbeing 

Starting today, Aegis Sciences Corporation will be joining the National Council for Mental Wellbeing in continuing to build momentum to the future of mental health and substance use treatment. Make sure to stop by our booth #1031 to learn more about how we can support medication adherence. Malissa Torre Hope Randle, PharmD, BCPS, BCPP Miranda Hughes #NatCon26 #AegisLabs #MentalHealth #BehavioiralHealth #Wellbeing 

Ahead of this year’s NatCon26 conference hosted by the National Council for Mental Wellbeing, we want to hear from you! What topic do you want to learn more about?    #NatCon26 #AegisLabs #MentalHealth #BehavioiralHealth #Wellbeing

Negative benzodiazepine screens do not always mean no benzodiazepines are present. Definitive LC-MS/MS testing continues to reveal clinically relevant exposures that routine Point-of-Care Testing (POCT) misses, including high-potency designer benzodiazepines increasingly found alongside opioids. In high-risk populations, relying on immunoassay results alone may underestimate sedation and overdose risk.   When the clinical picture does not match the screen, testing methodology matters. Accurate identification of exposure supports safer prescribing, better treatment planning, and more informed patient conversations in an evolving drug landscape. Learn more about the implications of POCT vs Definitive testing during our upcoming clinical webinar. Register today: https://lnkd.in/gBJhT3W3 #AegisLabs #Benzodiazepines #POCT #DefinitiveTesting #OverdoseRisk #Opioids #AddictionMedicine #PublicSafety

As the American Society of Addiction Medicine - ASAM Annual Conference 2026 continues, join us at Booth #800 to learn how Aegis toxicology testing supports informed, confident treatment decisions. Our team will be on site, including Dr. Clary, Clinical Pharmacist, who will be available to share clinical insights and answer questions about today’s rapidly evolving drug landscape.    Stop by to connect, learn, and see how Aegis helps providers put actionable data into practice. Julie Perkins Savannah Roberts Clary, Pharm.D., BCPS, CPGx Dwayne Young #ASAM #AC2026 #AegisLabs #AddictionMedicine #AddictionTreatment